AUTHOR=Yi Rongyuan , Lv Wanwan , Zheng Shan , Zhang Ningyu , Zhang Yuheng , Yang Kai , Huang Tuo , Yang Yanning , Chu Hui , Chen Jian 

TITLE=IFN-γ/Doxorubicin Complex Nanoparticles for Enhancing Therapy in the Context of Human Ovarian Carcinoma

JOURNAL=Frontiers in Materials

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/materials/articles/10.3389/fmats.2022.944930

DOI=10.3389/fmats.2022.944930

ISSN=2296-8016

ABSTRACT=The cytokine interferon gamma (IFN-γ) and doxorubicin mono-therapy has been approved by the Food and Drug Administration (FDA) for the treatment of anti-tumor. The importance of IFN-γ in the immune system lies in its immunomodulatory effects and the importance of doxorubicin in anti-tumor therapy lies in inhibiting RNS and DNA synthesis. In this work, the role of IFN-γ on the antitumor activity in combination with doxorubicin was investigated. Meanwhile, IFN-γ was used as vehicle to load doxorubicin over immunotherapy and chemotherapy for synergistic therapy. IFN-γ/doxorubicin complex nanoparticles were prepared by a fusion method with a size of approximately 13 nm and a low polydispersity index. The doxorubicin release profile was analyzed with different pH and it showed an enhanced release in acidic pH. The ability of IFN-γ/doxorubicin complex nanoparticles to induce human ovarian carcinoma cells (Skov 3) apoptosis was evaluated by cytotoxicity test. The cellular uptake of the IFN-γ/doxorubicin complex nanoparticles was time-dependent and the IFN-γ/doxorubicin complex nanoparticles showed a higher apoptosis efficiency than free doxorubicin by flow cytometry analysis and fluorescence imaging. This work bridged IFN-γ with doxorubicin to utilize their potential for antitumor, opening new avenues for their use in clinical settings.